Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: docetaxel

« Back to Dashboard

Summary for Generic Name: docetaxel

Tradenames:3
Patents:1
Applicants:9
NDAs:9
Drug Master File Entries: see list38
Suppliers: see list9

Pharmacology for Ingredient: docetaxel

Drug ClassMicrotubule Inhibitor
Physiological EffectMicrotubule Inhibition

Clinical Trials for: docetaxel

Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events
Status: Completed Condition: CYP3A Phenotyping; CYP3A5 and MDR1 Genotyping; Docetaxel Toxicity; Associations Between Genetic Data and Docetaxel Toxicity

Randomized Study of Docetaxel +/- ZD6474 in Metastatic TCC
Status: Completed Condition: Transitional Cell Carcinoma; Bladder Cancer

The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer
Status: Completed Condition: Nausea and Vomiting, Chemotherapy-Induced; Cancer

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
Status: Recruiting Condition: Hormone Refractory Prostate Cancer

BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I
Status: Active, not recruiting Condition: Carcinoma, Non-Small-Cell Lung

A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Status: Suspended Condition: Prostatic Neoplasms

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
Status: Completed Condition: Malignant Solid Tumor

Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
Status: Terminated Condition: Non-Small Cell Lung Cancer

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
Status: Completed Condition: Metastatic Prostate Cancer

Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Status: Completed Condition: Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Inc
DOCETAXEL
docetaxel
INJECTABLE;INJECTION203551Apr 12, 2013RXNo<disabled><disabled>
Accord Hlthcare
DOCETAXEL
docetaxel
INJECTABLE;INJECTION201195Jun 8, 2011RXNo<disabled><disabled>
Sun Pharma Global
DOCEFREZ
docetaxel
INJECTABLE;INJECTION022534May 3, 2011RXYes<disabled><disabled>
Accord Hlthcare
DOCETAXEL
docetaxel
INJECTABLE;INJECTION201195Apr 20, 2012RXYes<disabled><disabled>
Sanofi Aventis Us
TAXOTERE
docetaxel
INJECTABLE;INJECTION020449Aug 2, 2010RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc